SML0036
Procarbazine hydrochloride
≥98% (HPLC)
别名:
N-(1-Methylethyl)-4-[(2-methylhydrazinyl)methyl]benzamide hydrochloride
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H19N3O·HCl
化学文摘社编号:
分子量:
257.76
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
206-678-6
MDL number:
InChI key
DERJYEZSLHIUKF-UHFFFAOYSA-N
InChI
1S/C12H19N3O.ClH/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3;/h4-7,9,13-14H,8H2,1-3H3,(H,15,16);1H
SMILES string
Cl.CNNCc1ccc(cc1)C(=O)NC(C)C
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to tan
solubility
DMSO: ≥18 mg/mL
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
Procarbazine hydrochloride has been used to study its physicochemical property.
Procarbazine, an antineoplastic alkylating agent, may be used to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an anticancer agent. It may be used to study new combination of anticancer drugs.
Biochem/physiol Actions
Procarbazine hydrochloride is a Antineoplastic alkylating agent
Procarbazine is an antineoplastic alkylating agent widely used in cancer chemotherapy in combination with other compounds. It has multiple mechanisms of action. Procarbazine inhibits protein, RNA and DNA synthesis in addition to being an alkylating agent.
Procarbazine is metabolized to azoprocarbazine either by cytochrome P450 enzyme and monoamine oxidase in an NADPH (nicotinamide adenine diphosphate) dependent or independent manner. It is considered neurotoxic. Procarbazine is used in combination with therapy for treating Hodgkin′s disease.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Carc. 1B - Muta. 2 - Repr. 1A
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Anti-Cancer Drug Design, 143-143 (1994)
Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies.
Michaela Rancea et al.
Journal of the National Cancer Institute, 104(14), NP-NP (2012-07-25)
Mary R Welch et al.
Neuro-oncology, 14(10), 1304-1311 (2012-09-07)
Up to 20% of all primary CNS lymphoma (PCNLS) patients are aged 80 years or older, yet data are limited on how best to treat this rapidly growing population. Despite demographic pressures and the proven efficacy of methotrexate (MTX)-based regimens
L Kochbati et al.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 16(7), 627-632 (2012-10-23)
To assess the epidemiological, clinical and therapeutic aspects of pediatric Hodgkin disease (HD) and to study prognosis factors. We retrospectively reviewed the medical records of children (≤18 years) with HD treated between 1st January 1994 and 31st December 2004. Chemotherapy
Lale Erdem-Eraslan et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(3), 328-336 (2012-12-28)
Intrinsic glioma subtypes (IGSs) are molecularly similar tumors that can be identified based on unsupervised gene expression analysis. Here, we have evaluated the clinical relevance of these subtypes within European Organisation for Research and Treatment of Cancer (EORTC) 26951, a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持